NCT03785249 2025-09-30Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Mirati Therapeutics Inc.Phase 1/2 Active not recruiting731 enrolled 3 FDA
NCT00716417 2025-08-05Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid TumoursBoehringer IngelheimPhase 1 Completed47 enrolled 18 charts